SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - GBP (£) |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Prepaid Expenses And Other Current Assets | ||
Other receivables | £ 51,826 | £ 51,584 |
VAT owed to the Company | 66,957 | 135,642 |
Prepaid clinical trial costs | 307,519 | 307,519 |
Deferred clinical trial testing costs | 1,177,500 | 1,177,500 |
Other prepayments | 463,688 | 522,480 |
Total | £ 2,067,490 | £ 2,194,725 |
X | ||||||||||
- Definition Deferred clinical trial testing costs. No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Prepaid clinical trial costs. No definition available.
|
X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount due from parties in nontrade transactions, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|